Trial Profile
Phase II study of Paclitaxel and Epirubicin as Neoadjuvant Treatment for locally advanced Breast Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2016
Price :
$35
*
At a glance
- Drugs Epirubicin (Primary) ; Paclitaxel (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms NAB
- 05 Jul 2016 New trial record